CLIFFORD ROBERT JACK

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Magnetic resonance imaging research in aging and dementia at the Mayo Clinic
    Clifford R Jack
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN 55095, USA
    Alzheimer Dis Assoc Disord 22:204-8. 2008
  2. ncbi request reprint Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia
    Charles DeCarli
    Department of Neurology and Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis, Sacramento 95817, USA
    Arch Neurol 64:108-15. 2007
  3. pmc Rates of cerebral atrophy differ in different degenerative pathologies
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Brain 130:1148-58. 2007
  4. pmc Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI
    Clifford R Jack
    Department of Radiology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Neurobiol Aging 29:1285-95. 2008
  5. pmc Non-stationarity in the "resting brain's" modular architecture
    David T Jones
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e39731. 2012
  6. pmc Biomarker modeling of Alzheimer's disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA Electronic address
    Neuron 80:1347-58. 2013
  7. pmc Cerebral amyloid PET imaging in Alzheimer's disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic, Rochester, USA
    Acta Neuropathol 126:643-57. 2013
  8. pmc Resting state functional MRI in Alzheimer's Disease
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Alzheimers Res Ther 4:2. 2012
  9. pmc Brain β-amyloid load approaches a plateau
    Clifford R Jack
    From the Departments of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 80:890-6. 2013
  10. pmc Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
    Clifford R Jack
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet Neurol 12:207-16. 2013

Detail Information

Publications102 found, 100 shown here

  1. doi request reprint Magnetic resonance imaging research in aging and dementia at the Mayo Clinic
    Clifford R Jack
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN 55095, USA
    Alzheimer Dis Assoc Disord 22:204-8. 2008
  2. ncbi request reprint Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia
    Charles DeCarli
    Department of Neurology and Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis, Sacramento 95817, USA
    Arch Neurol 64:108-15. 2007
    ..Prognostic uncertainty suggests the need for additional measures to assist the clinician...
  3. pmc Rates of cerebral atrophy differ in different degenerative pathologies
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Brain 130:1148-58. 2007
    ....
  4. pmc Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI
    Clifford R Jack
    Department of Radiology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Neurobiol Aging 29:1285-95. 2008
    ..000). Results of this study support the feasibility of using MRI as an outcome measure of disease progression in multi center therapeutic trials for MCI...
  5. pmc Non-stationarity in the "resting brain's" modular architecture
    David T Jones
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e39731. 2012
    ..DMN dwell time in specific modular configurations may also underlie the TF-fMRI findings that have been described in mild cognitive impairment and cognitively normal subjects who are at risk for Alzheimer's dementia...
  6. pmc Biomarker modeling of Alzheimer's disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA Electronic address
    Neuron 80:1347-58. 2013
    ..In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly. ..
  7. pmc Cerebral amyloid PET imaging in Alzheimer's disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic, Rochester, USA
    Acta Neuropathol 126:643-57. 2013
    ....
  8. pmc Resting state functional MRI in Alzheimer's Disease
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Alzheimers Res Ther 4:2. 2012
    ..Then we present the current state of knowledge in this area by summarizing various AD resting-state fMRI studies presented in the first section and end with a discussion of future developments and open questions in the field...
  9. pmc Brain β-amyloid load approaches a plateau
    Clifford R Jack
    From the Departments of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 80:890-6. 2013
    ..To model the temporal trajectory of β-amyloid accumulation using serial amyloid PET imaging...
  10. pmc Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
    Clifford R Jack
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet Neurol 12:207-16. 2013
    ....
  11. pmc Shapes of the trajectories of 5 major biomarkers of Alzheimer disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Arch Neurol 69:856-67. 2012
    ..To characterize the shape of the trajectories of Alzheimer disease biomarkers as a function of Mini-Mental State Examination (MMSE) score...
  12. pmc An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Ann Neurol 71:765-75. 2012
    ..A workgroup commissioned by the Alzheimer's Association (AA) and the National Institute on Aging (NIA) recently published research criteria for preclinical Alzheimer disease (AD). We performed a preliminary assessment of these guidelines...
  13. pmc Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Radiology 263:344-61. 2012
    ..This presents an important opportunity that, if widely embraced, could greatly expand the application of imaging to improve clinical diagnosis and the quality and efficiency of clinical trials...
  14. pmc Alliance for aging research AD biomarkers work group: structural MRI
    Clifford R Jack
    Mayo Foundation, Rochester, MN 55905, USA
    Neurobiol Aging 32:S48-57. 2011
    ..Finally, the place of MRI in a hypothetical model of temporal ordering of AD biomarkers is reviewed...
  15. pmc Complexity in the genetic architecture of leukoaraiosis in hypertensive sibships from the GENOA Study
    Jennifer A Smith
    Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA
    BMC Med Genomics 2:16. 2009
    ....
  16. pmc Role of structural MRI in Alzheimer's disease
    Prashanthi Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Alzheimers Res Ther 2:23. 2010
    ....
  17. pmc Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Brain 133:3336-48. 2010
    ....
  18. pmc Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Alzheimers Dement 7:474-485.e4. 2011
    ..Hippocampal volumetry is the most widely studied quantitative magnetic resonance imaging measure in Alzheimer's disease and thus represents the most rational target for an initial effort at standardization...
  19. pmc Atrophy rates accelerate in amnestic mild cognitive impairment
    C R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 70:1740-52. 2008
    ..We included comparisons to subjects with aMCI who did not progress (labeled aMCI-S) and also to cognitively normal elderly subjects (CN)...
  20. pmc 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment
    Clifford R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Brain 131:665-80. 2008
    ..PiB and MRI provided complementary information such that clinical diagnostic classification using both methods was superior to using either in isolation...
  21. pmc The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods
    Clifford R Jack
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 27:685-91. 2008
    ..The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom-based monitoring of all scanners could be used as a model for other multisite trials...
  22. pmc Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
    Clifford R Jack
    Clifford R Jack, Mayo Clinic, Diagnostic Radiology, 200 First Street SW, Rochester, MN 55905, USA
    Brain 132:1355-65. 2009
    ..This model implies a complimentary role for MRI and PIB imaging in Alzheimer's disease, with each reflecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration...
  23. pmc Evidence for ordering of Alzheimer disease biomarkers
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Mayo Foundation for Medical Education and Research, 200 First St, SW, Rochester, MN 55905, USA
    Arch Neurol 68:1526-35. 2011
    ..To empirically assess the concept that Alzheimer disease (AD) biomarkers significantly depart from normality in a temporally ordered manner...
  24. pmc Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Alzheimers Dement 7:257-62. 2011
    ..Criteria for the clinical diagnosis of Alzheimer's disease (AD) were established in 1984. A broad consensus now exists that these criteria should be revised to incorporate state-of-the-art scientific knowledge...
  25. pmc Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative
    Clifford R Jack
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Alzheimers Dement 6:212-20. 2010
    ..These experimental sub-studies are designed to demonstrate the feasibility of acquiring useful data in a multicenter (but single vendor) setting for these three emerging MRI applications...
  26. ncbi request reprint Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research
    Clifford R Jack
    Mayo Clinic, Department of Radiology, 200 First Street SW, Rochester, MN 55905, USA
    Neuroscientist 13:38-48. 2007
    ..Toward the end of this review, the authors include results from a pilot study demonstrating feasibility of using MRMI to detect therapeutic modification of plaque progression in AD transgenic mice...
  27. pmc Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
    C R Jack
    Department of Diagnostic Radiology and MR Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 62:591-600. 2004
    ....
  28. pmc In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice
    Clifford R Jack
    Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Neurosci 25:10041-8. 2005
    ..In vivo MRI of individual Alzheimer's amyloid plaques provides a noninvasive estimate of plaque burden in transgenic AD mice that might be useful in assessing the efficacy of amyloid reduction therapies...
  29. pmc Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    NeuroRx 1:196-205. 2004
    ..As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD...
  30. pmc Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 65:1227-31. 2005
    ....
  31. pmc MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN, USA
    Neurology 60:253-60. 2003
    ..To assess the feasibility of using MRI measurements as a surrogate endpoint for disease progression in a therapeutic trial for AD...
  32. pmc In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent
    Clifford R Jack
    Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Magn Reson Med 52:1263-71. 2004
    ..To our knowledge this work represents the first demonstration of noninvasive in vivo visualization of individual AD plaques without the use of a contrast agent...
  33. pmc FLAIR histogram segmentation for measurement of leukoaraiosis volume
    C R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 14:668-76. 2001
    ..4% for leukoaraiosis volume and 0.3% for brain volume. We conclude that the FLAIR-histoseg method is an accurate and reproducible method for measuring leukoaraiosis and whole-brain volume in elderly subjects...
  34. ncbi request reprint Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging
    Joseph F Poduslo
    Molecular Neurobiology Laboratory, Department of Neurology, Mayo Clinic Rochester, Minnesota 55905, USA
    Neurobiol Dis 11:315-29. 2002
    ..This could enable early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed...
  35. pmc Prominent phenotypic variability associated with mutations in Progranulin
    Brendan J Kelley
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 30:739-51. 2009
    ..Some kindreds with PGRN mutations exhibited lateralized topography of degeneration across all affected individuals...
  36. pmc Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease
    Prashanthi Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Ann Neurol 67:308-16. 2010
    ....
  37. pmc Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neuroimage 39:1034-40. 2008
    ..The trajectories of brain and ventricular changes were similar in AD and FTLD-U suggesting that it is independent of pathology, although subjects with FTLD-U show a more rapidly progressive decline...
  38. pmc Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease
    Matthew L Senjem
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neuroimage 26:600-8. 2005
    ....
  39. pmc 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minnesota 55901, USA
    J Int Neuropsychol Soc 8:934-42. 2002
    ..Among 1H-MRS measurements, the NAA/MI ratio maybe the most efficient predictor of memory and cognitive function in patients with MCI and AD...
  40. pmc Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minn, USA
    Dement Geriatr Cogn Disord 14:198-207. 2002
    ..Selection of imaging measures used for clinical assessment or monitoring efficiency of therapeutic intervention should be tailored to the clinical stage of the disease...
  41. pmc 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Brain 130:1777-86. 2007
    ..These results also suggest that 3D patterns of grey matter atrophy may help to predict the time to the first diagnosis of AD in subjects with aMCI...
  42. pmc Functional impact of white matter hyperintensities in cognitively normal elderly subjects
    Melissa E Murray
    Department of Neuroscience Neuropathology, Mayo Clinic, Jacksonville, Florida, USA
    Arch Neurol 67:1379-85. 2010
    ..To investigate the impact white matter hyperintensities (WMH) detected on magnetic resonance imaging have on motor dysfunction and cognitive impairment in elderly subjects without dementia...
  43. pmc Common MRI acquisition non-idealities significantly impact the output of the boundary shift integral method of measuring brain atrophy on serial MRI
    Gregory M Preboske
    Mayo Clinic and Foundation, Department of Radiology, 200 First Street SW, Rochester, MN 55905, USA
    Neuroimage 30:1196-202. 2006
    ..Methods to maximize consistency of image quality over time are an essential component of any quantitative serial MRI study...
  44. pmc Patterns of atrophy differ among specific subtypes of mild cognitive impairment
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arch Neurol 64:1130-8. 2007
    ..It follows, however, that subjects with MCI who have impairment in nonmemory domains may progress to non-AD degenerative dementias...
  45. pmc Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations
    Jennifer L Whitwell
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 64:371-6. 2007
    ..Mutations in the progranulin gene (PGRN) have recently been identified as a cause of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) in some families...
  46. ncbi request reprint Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T
    Kejal Kantarci
    Department of Diagnostic Radiology, Milwaukee, WI, USA
    AJNR Am J Neuroradiol 24:843-9. 2003
    ..5 and 3 T to diagnostically discriminate among cognitively normal elderly subjects, patients with mild cognitive impairment (MCI), and patients with Alzheimer disease (AD)...
  47. pmc Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Brain 130:708-19. 2007
    ..Damage to this network of structures in DLB may affect a number of different neurotransmitter systems which in turn may contribute to a number of the core clinical features of DLB...
  48. pmc Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 66:102-4. 2006
    ..Patterns of atrophy were distinct and different from each other. A localized pattern of frontal lobe atrophy was found in FTLD-MND with a more widespread pattern of atrophy affecting the frontal and temporal lobes in FTLD-U...
  49. pmc Imaging correlates of posterior cortical atrophy
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 28:1051-61. 2007
    ..1)H MRS suggested loss of neuronal integrity and glial activation in subjects with PCA and typical AD. The differing patterns of atrophy on MRI suggest that PCA should be considered a distinct entity from typical AD...
  50. pmc Symmetric corticobasal degeneration (S-CBD)
    Anhar Hassan
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Parkinsonism Relat Disord 16:208-14. 2010
    ..Asymmetry is also emphasized on neuroimaging...
  51. pmc Predicting clinical scores from magnetic resonance scans in Alzheimer's disease
    Cynthia M Stonnington
    Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, AZ, USA
    Neuroimage 51:1405-13. 2010
    ..RVR offers a novel way to measure interactions between structural changes and neuropsychological tests beyond that of univariate methods. In clinical practice, we envision using RVR to aid in diagnosis and predict clinical outcome...
  52. pmc Very early semantic dementia with progressive temporal lobe atrophy: an 8-year longitudinal study
    Kathrin Czarnecki
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 65:1659-63. 2008
    ..Semantic dementia is a syndrome within the spectrum of frontotemporal lobar degenerations characterized by fluent progressive aphasia (particularly anomia) and loss of word meaning...
  53. pmc Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
    Clifford R Jack
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA jack cliff
    Lancet Neurol 9:119-28. 2010
    ....
  54. pmc Functional magnetic resonance imaging changes in amnestic and nonamnestic mild cognitive impairment during encoding and recognition tasks
    Mary M Machulda
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Int Neuropsychol Soc 15:372-82. 2009
    ..The diminished parietal and frontal activation in naMCI may reflect compromised ability to perform nonmemory (i.e., attention/executive, visuospatial function) components of the task...
  55. pmc Genomic susceptibility Loci for brain atrophy, ventricular volume, and leukoaraiosis in hypertensive sibships
    Stephen T Turner
    Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Arch Neurol 66:847-57. 2009
    ....
  56. pmc Mild cognitive impairment: ten years later
    Ronald C Petersen
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arch Neurol 66:1447-55. 2009
    ..This review summarizes the progress that has been made while also recognizing the challenges that remain...
  57. ncbi request reprint Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration
    Keith A Josephs
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 61:1881-4. 2004
    ..Various pathologic findings, including corticobasal degeneration (CBD), progressive supranuclear palsy, and frontotemporal degenerations, underlie CBS...
  58. pmc Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer's disease
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 25:1246-52. 2010
    ..In subjects presenting with CBS, prominent temporoparietal, especially posterior temporal and inferior parietal, atrophy may be a clue to the presence of underlying AD pathology...
  59. ncbi request reprint Measurement of cerebrospinal fluid flow at the cerebral aqueduct by use of phase-contrast magnetic resonance imaging: technique validation and utility in diagnosing idiopathic normal pressure hydrocephalus
    Patrick H Luetmer
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neurosurgery 50:534-43; discussion 543-4. 2002
    ....
  60. ncbi request reprint Transient postictal magnetic resonance imaging abnormality of the corpus callosum in a patient with epilepsy. Case report and review of the literature
    Aaron A Cohen-Gadol
    Department of Neurologic Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Neurosurg 97:714-7. 2002
    ..Benign and transient abnormalities in the splenium can occur as a periictal phenomenon. A high index of suspicion and follow-up imaging may prevent further unwarranted intervention...
  61. ncbi request reprint Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study
    Bradley F Boeve
    Department of Neurology, Mayo Clinic Rochester, MN 55905, USA
    Brain 129:3103-14. 2006
    ..These findings suggest that the insR352 PSEN1 is not pathogenic, and the IVS1+1G-->A mutation in PGRN causes FTDP associated with FTLD-U pathology and represents a new class of neurodegenerative disease--the 'hypoprogranulinopathies'...
  62. pmc Methodological considerations for measuring rates of brain atrophy
    Jeffrey L Gunter
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 18:16-24. 2003
    ..To systematically compare two techniques for measuring brain atrophy rates from serial magnetic resonance imaging (MRI) studies...
  63. ncbi request reprint Neuroimaging in Alzheimer disease: an evidence-based review
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neuroimaging Clin N Am 13:197-209. 2003
    ....
  64. doi request reprint Gray matter correlates of behavioral severity in progressive supranuclear palsy
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 26:493-8. 2011
    ..Behavioral changes occur in progressive supranuclear palsy. This study aimed to identify the anatomic correlate of behavioral severity in progressive supranuclear palsy...
  65. pmc Predicting functional decline in behavioural variant frontotemporal dementia
    Keith A Josephs
    Department of Neurology Behavioural Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Brain 134:432-48. 2011
    ....
  66. doi request reprint Default mode network disruption secondary to a lesion in the anterior thalamus
    David T Jones
    Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 68:242-7. 2011
    ..To describe the neuroanatomical correlations of an isolated lesion in the anterior thalamus using functional imaging in a 40-year-old man with multiple sclerosis...
  67. pmc Untreated type 2 diabetes and its complications are associated with subcortical infarctions
    Rosebud O Roberts
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
    Diabetes Care 34:184-6. 2011
    ..To investigate the association of type 2 diabetes with subcortical infarctions...
  68. pmc Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 65:1621-8. 2008
    ..Noninvasive imaging surrogates for underlying pathological findings in MCI would be clinically useful for identifying patients who may benefit from disease-specific treatments at the prodromal stage of dementia...
  69. pmc Beta-amyloid burden is not associated with rates of brain atrophy
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Neurol 63:204-12. 2008
    ..To test the hypothesis that beta-amyloid (Abeta) burden is associated with rates of brain atrophy...
  70. ncbi request reprint Neuroimaging in dementia
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurol Clin 25:843-57, viii. 2007
    ..The most important development in the field over the past decade is the ability to image amyloid in the brain. This technique will revolutionize patient management and care...
  71. pmc Anatomic correlates of stereotypies in frontotemporal lobar degeneration
    Keith A Josephs
    Department of Neurology, Behavioral Neurology and Movement Disorders, Mayo Clinic, Rochester, MN 55905, United States
    Neurobiol Aging 29:1859-63. 2008
    ..Stereotypies in FTLD are therefore associated with a greater proportion of striatal to cortical volume loss than those without stereotypies...
  72. ncbi request reprint Heritability of leukoaraiosis in hypertensive sibships
    Stephen T Turner
    Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Hypertension 43:483-7. 2004
    ..671+/-0.110 (P<0.0001). This evidence of strong genetic influence on the susceptibility to leukoaraiosis justifies efforts to localize the responsible genes and characterize the predisposing genetic polymorphisms...
  73. ncbi request reprint Frontotemporal lobar degeneration without lobar atrophy
    Keith A Josephs
    Department of Neurology, Division of Behavioral Neurology and Movement Disorders, Mayo Clinic, Rochester, MN 55905, USA
    Arch Neurol 63:1632-8. 2006
    ..Neuronal loss and gliosis in cornu ammonis 1 and the subiculum of the hippocampus are features of hippocampal sclerosis (HpScl), which occurs in many cases of FTLD-U...
  74. pmc Voxel-based morphometry in autopsy proven PSP and CBD
    Keith A Josephs
    Department of Neurology Movement Disorders, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 29:280-9. 2008
    ..These results show regional differences between PSP and CBD that are useful in predicting the underlying pathology, and help to shed light on the in vivo distribution of regional atrophy in PSP and CBD...
  75. ncbi request reprint Comparisons between Alzheimer disease, frontotemporal lobar degeneration, and normal aging with brain mapping
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Top Magn Reson Imaging 16:409-25. 2005
    ..This article will review the findings of these studies and discuss the role of VBM in these neurodegenerative diseases...
  76. pmc Visual hallucinations in posterior cortical atrophy
    Keith A Josephs
    Divisions of Movement Disorders and Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, Minn, USA
    Arch Neurol 63:1427-32. 2006
    ..It is not known, however, whether patients who meet the criteria for PCA and have hallucinations are different from those who meet the criteria and do not have hallucinations...
  77. pmc Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurobiol Aging 28:1330-9. 2007
    ..Choline/creatine ratio declined in stable MCI, compared to converter MCI patients and cognitively normal elderly, which may be related to a compensatory mechanism in MCI patients who did not to progress to AD...
  78. pmc Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech
    Keith A Josephs
    Department of Neurology, Division of Movement Disorders and Behavioral Neurology, Mayo Clinic, Rochester, MN 55905
    Brain 129:1385-98. 2006
    ..Refining the classification of the degenerative aphasias and AOS may be necessary to improve our understanding of the relationships among behavioural, pathological and imaging correlations...
  79. pmc Interpreting scan data acquired from multiple scanners: a study with Alzheimer's disease
    Cynthia M Stonnington
    Wellcome Trust Centre for Neuroimaging, Institute of Neurology, UCL, London, UK
    Neuroimage 39:1180-5. 2008
    ..Similar analyses in other multi-scanner data-sets could be used to justify the pooling of data when needed, such as in studies of rare disorders or in multi-center designs...
  80. pmc Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships
    David S Knopman
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, United States
    J Neurol Sci 271:53-60. 2008
    ..Because of similarities between brain and kidney microvascular disease, there may be a relationship between measures of renal microvascular disease and brain structural changes in middle aged or elderly individuals...
  81. pmc Measurement of MRI scanner performance with the ADNI phantom
    Jeffrey L Gunter
    Mayo Clinic and Foundation, Rochester, Minnesota 55902, USA
    Med Phys 36:2193-205. 2009
    ..If undetected, these errors would have contributed to imprecision in quantitative metrics at over 25% of all enrolling ADNI sites...
  82. doi request reprint MR microimaging of amyloid plaques in Alzheimer's disease transgenic mice
    Thomas M Wengenack
    Molecular Neurobiology Laboratory, Departments of Neurology, Neuroscience, and Biochemistry Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur J Nucl Med Mol Imaging 35:S82-8. 2008
    ....
  83. pmc Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging
    Muthu Ramakrishnan
    Molecular Neurobiology Laboratory, Departments of Neurology and Neuroscience, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905, USA
    Pharm Res 25:1861-72. 2008
    ..We describe the development of a contrast agent (CA) for magnetic resonance microimaging that utilizes the F(ab')2 fragment of a monoclonal antibody raised against fibrillar human Abeta42..
  84. pmc Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neuroimage 55:522-31. 2011
    ..8%). The proposed approach establishes a direct a priori relationship between specific topographic patterns on MRI and "gold standard" of pathology which can then be used to predict underlying dementia pathology in new incoming patients...
  85. pmc Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements
    Kejal Kantarci
    Departments of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 248:210-20. 2008
    ..To determine the neuropathologic correlates of antemortem hydrogen 1 ((1)H) magnetic resonance (MR) spectroscopy metabolite measurements in subjects with Alzheimer disease (AD)-type pathology...
  86. pmc Comparison of 18F-FDG and PiB PET in cognitive impairment
    Val J Lowe
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Nucl Med 50:878-86. 2009
    ..The purpose of this study was to compare the diagnostic accuracy of glucose metabolism and amyloid deposition as demonstrated by (18)F-FDG and Pittsburg Compound B (PiB) PET to evaluate subjects with cognitive impairment...
  87. ncbi request reprint Association of ambulatory blood pressure with ischemic brain injury
    Gary L Schwartz
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hypertension 49:1228-34. 2007
    ..009 for each). Higher ambulatory blood pressure levels and a nondipping circadian pattern contribute to greater leukoaraiosis volume after controlling for office blood pressure...
  88. pmc Age-related changes in the default mode network are more advanced in Alzheimer disease
    D T Jones
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 77:1524-31. 2011
    ..To investigate age-related default mode network (DMN) connectivity in a large cognitively normal elderly cohort and in patients with Alzheimer disease (AD) compared with age-, gender-, and education-matched controls...
  89. ncbi request reprint Family-based association study of matrix metalloproteinase-3 and -9 haplotypes with susceptibility to ischemic white matter injury
    Myriam Fornage
    Institute of Molecular Medicine, University of Texas Health Science Center at Houston, 1825 Pressler St, Room 530 G, Houston, TX 77030, USA
    Hum Genet 120:671-80. 2007
    ..They provide the basis for further investigation of the role of these genes in susceptibility and/or progression to clinical disease...
  90. ncbi request reprint Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial
    Michael Grundman
    Department of Neurosciences, University of California, San Diego, La Jolla, USA
    J Mol Neurosci 19:23-7. 2002
    ..In summary, these data suggest that MRI hippocampal volume may be a useful correlate of disease severity in MCI subjects and a prognostic indicator of subsequent AD...
  91. ncbi request reprint Neuroprotective effect of Coenzyme Q10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein
    Geng Li
    Jockey Club MRI Center, Faculty of Medicine, The University of Hong Kong, Hong Kong, China
    Neurobiol Aging 28:877-82. 2007
    ..We conclude that CoQ10 has a protective effect on the brain from infarction and atrophy induced by ischemic injury in aged and susceptible transgenic mice...
  92. ncbi request reprint Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation
    Bradley F Boeve
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, MN 55905, USA
    Brain 128:752-72. 2005
    ..These findings have implications for future drug trial development in FTDP-17 and the sporadic tauopathies...
  93. ncbi request reprint Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Michael Grundman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
    Arch Neurol 61:59-66. 2004
    ..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
  94. pmc Argyrophilic grains: a distinct disease or an additive pathology?
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 29:566-73. 2008
    ..Argyrophilic grains (AG) are silver-positive spindle-shaped lesions found at postmortem. Their significance is controversial...
  95. pmc 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry
    Xue Hua
    Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, Neuroscience Research Building 225E, Los Angeles, CA 90095 1769, USA
    Neuroimage 41:19-34. 2008
    ..In the future, TBM may help to (1) identify factors that resist or accelerate the disease process, and (2) measure disease burden in treatment trials...
  96. pmc Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy
    Malgorzata Marjanska
    Center for Magnetic Resonance Research and Department of Radiology, University of Minnesota, Minneapolis, MN 55455, USA
    Proc Natl Acad Sci U S A 102:11906-10. 2005
    ..Because of its noninvasive and repeatable nature, MRS in transgenic models of AD could substantially accelerate drug discovery for this disease...
  97. ncbi request reprint Genomic susceptibility loci for brain atrophy in hypertensive sibships from the GENOA study
    Stephen T Turner
    Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Hypertension 45:793-8. 2005
    ....
  98. pmc Automatic classification of MR scans in Alzheimer's disease
    Stefan Kloppel
    Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University College London, London, UK
    Brain 131:681-9. 2008
    ..Thirdly, the method is robust and can be generalized across different centres. This suggests an important role for computer based diagnostic image analysis for clinical practice...
  99. ncbi request reprint Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment
    Michael Grundman
    Department of Neurosciences, University of California, San Diego, La Jolla 92093 0949, USA
    J Mol Neurosci 20:241-8. 2003
    ..We conclude that the relationship between hippocampal volume and risk of AD is likely tied to reduced memory performance and not associated with impairment in nonmemory cognitive domains...
  100. ncbi request reprint Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment
    Adam Fleisher
    Department of Neurosciences, University of California San Diego, La Jolla, Calif, USA
    Arch Neurol 62:953-7. 2005
    ..The presence of the apolipoprotein E epsilon4 (APOE*E4) allele has been associated with greater hippocampal atrophy in women than in men with Alzheimer disease. This relationship has not been demonstrated in MCI...
  101. pmc Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils
    Richard G Boyes
    Dementia Research Centre, Institute of Neurology, Box 16, University College London, Queen Square, London, UK
    Neuroimage 39:1752-62. 2008
    ....

Research Grants23

  1. PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCE
    Clifford Jack; Fiscal Year: 2002
    ..We will test the hypothesis that specific MR measures are associated with decline in specific measures of cognition. ..
  2. MRI Biomarkers of Risk and Progression in Alzheimer's
    Clifford Jack; Fiscal Year: 2007
    ..Results from this project will provide new information that address an area identified as high priority for research by both the National Institute on Aging and the FDA. ..
  3. MRI Biomarkers of Risk and Progression in Alzheimer's
    Clifford Jack; Fiscal Year: 2003
    ..Results from this project will provide new information that address an area identified as high priority for research by both the National Institute on Aging and the FDA. ..
  4. Alzheimer's Diagnosis by Real-Time Motion Corrected FMRI
    Clifford Jack; Fiscal Year: 2004
    ..Aim number 4: to assess motion corrected fMRI as a diagnostic test for early Alzheimer's disease. ..
  5. MRI Biomarkers of Risk and Progression in Alzheimer's
    Clifford Jack; Fiscal Year: 2004
    ..Results from this project will provide new information that address an area identified as high priority for research by both the National Institute on Aging and the FDA. ..
  6. MRI Biomarkers of Risk and Progression in Alzheimer's
    Clifford Jack; Fiscal Year: 2005
    ..Results from this project will provide new information that address an area identified as high priority for research by both the National Institute on Aging and the FDA. ..
  7. MRI Biomarkers of Risk and Progression in Alzheimer's
    Clifford Jack; Fiscal Year: 2006
    ..Results from this project will provide new information that address an area identified as high priority for research by both the National Institute on Aging and the FDA. ..
  8. Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging
    Clifford Jack; Fiscal Year: 2008
    ..In this grant, we will use modern brain imaging to identify specific mechanisms underlying progression to dementia. [unreadable] [unreadable] [unreadable]..
  9. Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging
    Clifford Jack; Fiscal Year: 2009
    ..In this grant, we will use modern brain imaging to identify specific mechanisms underlying progression to dementia. ..
  10. Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging
    CLIFFORD ROBERT JACK; Fiscal Year: 2010
    ..In this grant, we will use modern brain imaging to identify specific mechanisms underlying progression to dementia. ..
  11. Alzheimer's Diagnosis by Real-Time Motion Corrected FMRI
    Clifford Jack; Fiscal Year: 2003
    ..Aim number 4: to assess motion corrected fMRI as a diagnostic test for early Alzheimer's disease. ..
  12. Alzheimer's Diagnosis by Real-Time Motion Corrected FMRI
    Clifford Jack; Fiscal Year: 2002
    ..Aim number 4: to assess motion corrected fMRI as a diagnostic test for early Alzheimer's disease. ..
  13. MR HIPPOCAMPAL CHANGES IN ALZHEIMER'S DISEASE AND AGING
    Clifford Jack; Fiscal Year: 1993
    ..This proposal represents a unique opportunity at this point in time to maximally utilize existing resources to address important issues regarding the role of MR volume try in improving the early diagnosis of DAT...
  14. PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCE
    Clifford Jack; Fiscal Year: 1999
    ..We will test the hypothesis that specific MR measures are associated with decline in specific measures of cognition. ..
  15. PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCE
    Clifford Jack; Fiscal Year: 2000
    ..We will test the hypothesis that specific MR measures are associated with decline in specific measures of cognition. ..
  16. PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCE
    Clifford Jack; Fiscal Year: 2001
    ..We will test the hypothesis that specific MR measures are associated with decline in specific measures of cognition. ..
  17. Alzheimer's Diagnosis by Real-Time Motion Corrected FMRI
    Clifford Jack; Fiscal Year: 2001
    ..Aim number 4: to assess motion corrected fMRI as a diagnostic test for early Alzheimer's disease. ..
  18. Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging
    Clifford Jack; Fiscal Year: 2009
    ..Dementia has many possible underlying causes and several different causes are at work in most elderly demented subjects. In this grant, we will use modern brain imaging to identify specific mechanisms underlying progression to dementia. ..